Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
SAR-bisPSMA's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for SAR-bisPSMA. Showing past 6 months and next 12 months · 1 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| SAR-bisPSMA | Clarity Pharmaceuticals | PSMA radioligand | Phase 3 | 0 | ||||
| [18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer | FutureChem | — |
Read-across commentary attached per trial. Phase ordering preserved within each group.
External analyst notes, journalism, and industry commentary cited with attribution.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
| — |
| — |
| — |
| — |
| — |
| Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer. | Yunhe Pharmaceutical (Tianjin) Co., Ltd | — | Phase 3 | — | — | — | — | — |
| Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging | ECOG-ACRIN Cancer Research Group | — | Phase 3 | — | — | — | — | — |
| PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores | H. Lee Moffitt Cancer Center and Research Institute | — | PHASE2/PHASE3 | — | — | — | — | — |
| An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer | University of Washington | — | Phase 2 | — | — | — | — | — |
| Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer. | CHU de Quebec-Universite Laval | — | Phase 2 | — | — | — | — | — |
| Phase II Trial to Investigate the Safety and Efficacy of Four Dosing Regimens of OTL78 Injection | Clinton Bahler | — | Phase 2 | — | — | — | — | — |
| Using FAPI PET/MRI to Evaluate Prostate Cancer | University of Wisconsin, Madison | — | Phase 2 | — | — | — | — | — |
| 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer | National Cancer Institute (NCI) | — | Phase 2 | — | — | — | — | — |
| Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer | Mayo Clinic | — | Phase 2 | — | — | — | — | — |
| 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer | National Cancer Institute (NCI) | — | Phase 2 | — | — | — | — | — |
| 64Cu-GRIP B in Patients With Advanced Malignancies | Rahul Aggarwal | — | PHASE1/PHASE2 | — | — | — | — | — |